Clik here to view.
venBio Calls on Immunomedics Stockholders to Support Meaningful Change
Monday, January 30th 2017 at 2:00pm UTC Cites Company’s Repeated Attempts to Mislead Stockholders Highlights Newly-Appointed Directors’ Lack of Preparedness to Act in Best Interest of Stockholders...
View ArticleClik here to view.
Teva Confirms District Court Decision in COPAXONE® 40 mg/mL Patent Trial
Monday, January 30th 2017 at 11:52pm UTC JERUSALEM–(BUSINESS WIRE)– Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today confirmed the U.S. District Court for the District of Delaware...
View ArticleClik here to view.
Taro to Announce Third Quarter Results on February 9, 2017
Tuesday, January 31st 2017 at 10:17pm UTC HAWTHORNE, N.Y.–(BUSINESS WIRE)– Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the...
View ArticleClik here to view.
Synergy Pharmaceuticals Announces Proposed Public Offering of Common Stock
Tuesday, January 31st 2017 at 9:01pm UTC NEW YORK–(BUSINESS WIRE)– Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a biopharmaceutical company focused on the development and commercialization of novel...
View ArticleClik here to view.
Acorda to Host Conference Call to Discuss Fourth Quarter 2016 on February 14,...
Tuesday, January 31st 2017 at 12:00pm UTC ARDSLEY, N.Y.–(BUSINESS WIRE)– Acorda Therapeutics, Inc. (Nasdaq:ACOR) will host a conference call and webcast to report its fourth quarter 2016 financial...
View ArticleClik here to view.
PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2016 RESULTS
Tuesday, January 31st 2017 at 11:45am UTC PROVIDES 2017 FINANCIAL GUIDANCE Full-Year 2016 Revenues of $52.8 Billion, Reflecting 11% Operational Growth; Full-Year 2016 Revenues for Pfizer Standalone...
View ArticleClik here to view.
Angion Biomedica Corp.’s Phase 2 “GUARD” Clinical Trial of BB3 in Acute...
Tuesday, January 31st 2017 at 1:00pm UTC UNIONDALE, N.Y.–(BUSINESS WIRE)– Angion Biomedica Corp. announced today that its Phase 2 “GUARD” clinical trial (GUard Against Renal Damage) using...
View ArticleClik here to view.
Synergy Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Wednesday, February 1st 2017 at 1:00pm UTC NEW YORK–(BUSINESS WIRE)– Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a biopharmaceutical company focused on the development and commercialization of novel...
View ArticleClik here to view.
Ophthotech Announces Strategic Review Plan
Wednesday, February 1st 2017 at 11:30am UTC – Plan Designed to Evaluate Strategic Alternatives and Maximize Shareholder Value – – Announces Executive Changes: Glenn P. Sblendorio Assumes the Position...
View ArticleClik here to view.
Teva to Report Fourth Quarter 2016 Financial Results on February 13, 2017
Wednesday, February 1st 2017 at 8:01pm UTC JERUSALEM–(BUSINESS WIRE)– Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it will release its fourth quarter 2016 financial results on...
View ArticleClik here to view.
Seres Therapeutics Announces Participation at Two Upcoming Investor Conferences
Friday, February 3rd 2017 at 12:00pm UTC CAMBRIDGE, Mass.–(BUSINESS WIRE)– Seres Therapeutics Inc., (NASDAQ:MCRB), a leading microbiome therapeutics platform company, today announced that management...
View ArticleClik here to view.
Lysogene Receives Orphan Drug Designation from FDA for LYS-GM101 for...
Thursday, February 2nd 2017 at 6:05pm UTC PARIS–(BUSINESS WIRE)– Lysogene (Paris:LYS), a leading, clinical-stage biotechnology company specializing in gene therapy for rare central nervous system...
View ArticleClik here to view.
Acorda Therapeutics to Present at Two Investor Conferences in February
Friday, February 3rd 2017 at 12:00pm UTC ARDSLEY, N.Y.–(BUSINESS WIRE)– Acorda Therapeutics, Inc. (Nasdaq:ACOR) announced that the Company will present at two investor conferences during February....
View ArticleClik here to view.
22nd Century Prevails Again in Frivolous Crede Lawsuit
Friday, February 3rd 2017 at 2:45pm UTC CLARENCE, N.Y.–(BUSINESS WIRE)– 22nd Century Group, Inc. (NYSE MKT:XXII), a plant biotechnology company that is a leader in tobacco harm reduction, announced...
View ArticleClik here to view.
OrbiMed Comments on Immunomedics Proxy Contest
Thursday, February 2nd 2017 at 7:25pm UTC NEW YORK–(BUSINESS WIRE)– OrbiMed Advisors LLC (“OrbiMed”), on behalf of its clients, has evaluated the proxy proposals from both Immunomedics, Inc....
View ArticleClik here to view.
Akebia to Present at the 19th BIO CEO & Investor Conference
Friday, February 3rd 2017 at 1:30pm UTC CAMBRIDGE, Mass.–(BUSINESS WIRE)– Akebia Therapeutics, Inc. (NASDAQ: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients...
View ArticleClik here to view.
Pfizer Commences $5 Billion Accelerated Share Repurchase
Friday, February 3rd 2017 at 1:10pm UTC Accelerated Share Repurchase Assumed in Pfizer’s 2017 Financial Guidance Issued on January 31, 2017 NEW YORK–(BUSINESS WIRE)– Pfizer Inc. (NYSE: PFE) today...
View ArticleClik here to view.
Eleven Biotherapeutics to Present at the 2017 BIO CEO & Investor Conference
Tuesday, February 7th 2017 at 1:00pm UTC CAMBRIDGE, Mass.–(BUSINESS WIRE)– Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing a broad pipeline of novel...
View ArticleClik here to view.
Cellectis to Present at the LEERINK Partners 6th Annual Global Healthcare...
Tuesday, February 7th 2017 at 9:48pm UTC NEW YORK–(BUSINESS WIRE)– class= »bwalignl »> Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS; Nasdaq: CLLS), a biopharmaceutical...
View ArticleClik here to view.
RaNA Therapeutics to Present at BIO CEO & Investor Conference
Tuesday, February 7th 2017 at 12:30pm UTC CAMBRIDGE, Mass.–(BUSINESS WIRE)– RaNA Therapeutics, a leader in the discovery and development of a new class of medicines that target RNA, today announced...
View Article